Coherus’s Low List Price Adalimumab Stacking Up PBM And Pharmacy Partnerships

Analysts Still Confident In Humira’s Market Share Despite Increasing Competition

 
• By Chloe Kent
  
Generate a summary of this article
Listen to this article
Beta

Coherus has made deals with numerous pharmacy benefit managers and pharmacies to bring its low list price Yusimry adalimumab biosimilar to patients, as analysts continue to back Humira originator AbbVie as market leader. 

Yusimry pen and packaging
Two PBMs have agreed to supply Yusimry through the Mark Cuban Cost Plus Drug Company • Source: Coherus Biosciences

Coherus Biosciences has made a number of distribution deals to bring its Humira (adalimumab) biosimilar Yusimry (adalimumab-aqvh) to patients, as a second pharmacy benefit manager steps up to offer the drug to its members through Mark Cuban Cost Plus Drug Company. The biosimilar developer has also struck a national distribution agreement for Yusimry through specialty pharmacy Superior Biologics.

PBMs SmithRx and RxPreferred are now both offering Yusimry through Mark Cuban Cost Plus Drug Company, an online pharmacy launched...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

GB-ProductsBiosimilars-Free-Commentary-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

GB-Premium-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Products

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Has An Ally In Argentina On Infliximab

Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.